Immune-modulating cancer drugs in clinical trials
Raised to date
$2.3M
of $46.1M offered across 5 Form D filings
Phio Pharmaceuticals Corp. is a biotechnology company specializing in the development of groundbreaking therapeutics, particularly in the field of immuno-oncology. Utilizing their proprietary technology platform, they focus on addressing unmet medical needs to potentially enhance cancer treatment outcomes.
What sets Phio Pharmaceuticals apart is their proprietary technology platform that supports both independent and collaborative therapeutic developments, leveraging intellectual property to maintain a competitive edge in the field.
$25.9M round, first sold Nov 2025: $1.4M sold, $24.5M still open
$25.9M round, first sold Nov 2025: $1.4M sold, $24.5M still open
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Nov 12, 2025 | Security to be acquired | $1.4M/ $25.9M | Form D |
| Aug 4, 2025 | Security to be acquired | $232K/ $5.1M | Form D |
| Jan 28, 2025 | Security to be acquired | $266K/ $6.4M | Form D |
| Jan 28, 2025 | Security to be acquired | $208K/ $5M | Form D |
| Jan 28, 2025 | Security to be acquired | $153K/ $3.7M | Form D |
Cancer immunotherapeutic
PH-762 is the flagship product candidate of Phio Pharmaceuticals, currently in clinical studies. It shows promising potential in enhancing cancer treatment by modulating immune responses to improve therapy outcomes.
Built for
Pharmaceutical companies and clinical research organizations
